Device Trial Radar · NCT02835391
PerClot Compared to Usual Care in Gynaecology Procedures
Last checked: Nov 19, 2026Latest source record: Sep 1, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
90
Actual
Start
Nov 2015
Primary completion
Jul 2017
Study completion Aug 2017
Sponsor
- Lead sponsor
- CryoLife EuropaPublic (AORT)
- Sponsor type
- Industry
- First posted
- Jul 18, 2016
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a post market, multi-centre, randomised study evaluating PerClot compared to usual care. PerClot is a CE marked device and is currently used as a haemostat in gynaecological surgery throughout Europe. The purpose of this study is to collect additional post market data on its use in this indication.
Conditions
- Endometriosis
- Ovarian Cyst
- Menorrhagia
- Cancer
- Uterine Fibroids
Interventions
PerClotDevice
Haemostatic device for the control of bleeding from capillary, venous or arteriolar vessels by pressure, ligature or other conventional means is either ineffective or impractical.
Floseal, Surgicel, Surgiflo, AristaDevice
Haemostatic device for the control of bleeding
Electrocautery/DiatermyProcedure
Procedure for the control of bleeding
Primary outcomes
What the sponsor says the trial is designed to measure.
- achievement of haemostasis (yes/no).Time frame: measured up to 10 minutes after application
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Bellvitge Hospital
Barcelona, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.